

1
SEQUENCE LISTING

<110> MEDIMMUNE LIMITED

<120> COMPOUNDS AND CONJUGATES THEREOF

<130> TOP-100-WO-PCT

<140>

<141>

<150> 62/964,177

<151> 2020-01-22

<150> 62/826,393

<151> 2019-03-29

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<400> 1

Asn	Ala	Val	Pro	Asn	Leu	Arg	Gly	Asp	Leu	Gln	Val	Leu	Ala	Gln	Lys
1				5				10						15	

Val	Ala	Arg	Thr	Cys
			20	

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<220>

<221> MOD_RES

<222> (4)..(18)

<223> Any amino acid

<400> 2

Asn Ala Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Arg Thr Cys
20

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<400> 3

Gly Gly Phe Gly
1

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<400> 4

Gly Phe Gly Gly
1